Investment analysts at Ladenburg Thalmann began coverage on shares of Biota Pharmaceuticals Inc. (NASDAQ:AVIR) in a note issued to investors on Wednesday. The firm set a “buy” rating on the stock.

Other equities research analysts also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating on shares of Biota Pharmaceuticals in a research report on Tuesday. FBR & Co reissued an “outperform” rating on shares of Biota Pharmaceuticals in a research report on Tuesday, May 31st. Five analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus price target of $5.50.

Biota Pharmaceuticals (NASDAQ:AVIR) traded up 3.12% on Wednesday, reaching $1.65. 119,510 shares of the company traded hands. The company’s market capitalization is $63.76 million. The company has a 50-day moving average price of $1.38 and a 200-day moving average price of $1.46. Biota Pharmaceuticals has a 12 month low of $1.23 and a 12 month high of $2.31.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/biota-pharmaceuticals-inc-avir-earns-buy-rating-from-analysts-at-ladenburg-thalmann.html

Biota Pharmaceuticals (NASDAQ:AVIR) last released its earnings results on Wednesday, September 14th. The company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.25 by $0.43. Biota Pharmaceuticals had a negative return on equity of 46.02% and a negative net margin of 272.04%. Equities research analysts expect that Biota Pharmaceuticals will post ($0.89) EPS for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. California Public Employees Retirement System acquired a new position in Biota Pharmaceuticals during the second quarter valued at approximately $139,000. BlackRock Fund Advisors acquired a new position in Biota Pharmaceuticals during the second quarter valued at approximately $143,000. Towerview LLC acquired a new position in Biota Pharmaceuticals during the second quarter valued at approximately $224,000. Dimensional Fund Advisors LP acquired a new position in Biota Pharmaceuticals during the second quarter valued at approximately $290,000. Finally, BVF Inc. IL acquired a new position in Biota Pharmaceuticals during the second quarter valued at approximately $292,000. 34.53% of the stock is owned by institutional investors and hedge funds.

About Biota Pharmaceuticals

Aviragen Therapeutics, Inc, formerly Biota Pharmaceuticals Inc, is a biopharmaceutical company. The Company is focused on the discovery and development of direct-acting antivirals to treat infections. It has approximately four product candidates in clinical development that address viral infections that have limited therapeutic options.

5 Day Chart for NASDAQ:AVIR

Receive News & Ratings for Biota Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biota Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.